Quick Dispatch:
Your tirzepatide surpass-5 Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics | Diabetes Therapy orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide surpass-5 Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics | Diabetes Therapy ships.
Need Help?
Questions about tirzepatide surpass-5 Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics | Diabetes Therapy, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide surpass-5 Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics | Diabetes Therapy in your area.
An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists
23.38
Tirzepatide Significantly Reduced A1C and Body Weight in People with Type 2 Diabetes in Two Phase 3 Trials from Lilly's SURPASS Program-CliniExpert
21.36
How did Mounjaro® (tirzepatide) compare with placebo as add-on to titrated insulin glargine with or without metformin in SURPASS-5?
22.29
Media Centre
29.20
Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT
27.10
Results of SURPASS-1-5 for tirzepatide treatment in T2D
24.32
Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program | Cardiovascular Diabetology
26.79
